Loading...
XNAS
MXCT
Market cap137mUSD
Jul 09, Last price  
1.28USD
1D
0.00%
1Q
61.74%
IPO
-21.47%
Name

MaxCyte Inc

Chart & Performance

D1W1MN
XNAS:MXCT chart
P/E
—
P/S
4.15
EPS
—
Div Yield, %
—
Shrs. gr., 5y
8.91%
Rev. gr., 5y
4.76%
Revenues
33m
-14.50%
5,059,5006,805,0007,164,4009,290,30012,269,50013,985,00016,667,00021,620,70026,168,90033,894,10044,261,00041,288,00038,627,00033,026,000
Net income
-45m
L+8.71%
-1,988,400-958,200-1,837,000-1,445,500-3,345,500-9,917,000-8,869,200-12,895,000-11,816,400-19,082,200-23,571,000-37,923,000-41,055,000-44,630,000
CFO
-34m
L+24.63%
-2,125,700-557,800-1,925,600-180,500-2,335,000-9,677,100-10,487,400-8,802,500-8,782,100-10,679,600-14,782,900-21,686,000-27,610,000-34,410,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes cell therapeutics in the United States and internationally. The company's products consists of ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. It also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. The company licenses and sells its instruments and technology; and sells its consumables to developers of cell therapies, as well as to pharmaceutical and biotechnology companies for use in drug discovery and development, and bio-manufacturing. MaxCyte, Inc. was incorporated in 1998 and is headquartered in Rockville, Maryland.
URL
https://www.maxcyte.com/
IPO date
Mar 29, 2016
Employees
125
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT